JPRN-UMIN000049834
Completed
未知
Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals - Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals
ConditionsCOVID-19
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- The Jikei University School of Medicine
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •If the applicant does not meet the age criteria or it is difficult to obtain his/her consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ELISPOT assay using induced sputumCertain infectious and parasitic diseasesKCT0000376Pusan National University Yangsan Hospital40
Completed
Not Applicable
tility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of infection in kidney transplant recipientsInfection in kidney transplant recipientsCMVBK virusinterferonelispotimmunityimmunocompromisedTCTR20210216004Ramathibodi Hospital100
Active, not recruiting
Phase 1
Sensing using Neutrophil Activation Probe on the Intensive Therapy UnitCritical illness requiring ventilationMedDRA version: 20.0Level: PTClassification code 10077264Term: Critical illnessSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: LLTClassification code 10003541Term: Assisted ventilationSystem Organ Class: 100000004865Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2015-005676-25-GBniversity of Edinburgh75
Not yet recruiting
Not Applicable
To find Natural killers cells as a treatment option for Triple negative breast cancer.Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2023/10/058292Tata Memorial Center
Not yet recruiting
Not Applicable
Discovery of biomarkers for immune-mediated liver disease.autoimmune hepatitis, drug-induced liver injury, non-alcoholic fatty liver disease and non-alcoholic steatohepatitisNL-OMON24228Investigator initiated study, funded by the Vrije Universiteit, University Medical Center